2021
Invasive thymoma – Which patients benefit from post-operative radiotherapy?
Muslim Z, Baig MZ, Weber JF, Detterbeck FC, Connery CP, Spera JA, Bhora FY. Invasive thymoma – Which patients benefit from post-operative radiotherapy? Asian Cardiovascular And Thoracic Annals 2021, 29: 935-942. PMID: 33975467, DOI: 10.1177/02184923211017094.Peer-Reviewed Original ResearchConceptsPost-operative radiotherapyWorld Health Organization histologyMasaoka-Koga stageStage III thymomaPropensity-matched cohortStage III diseaseClinical pathological factorsEnd Results (SEER) databasePositive prognostic indicatorUnderwent surgerySurgical treatmentThymoma patientsAdvanced thymomaB3 tumorsPrognostic implicationsResults databaseTumor sizeInvasive thymomaPrognostic indicatorSurvival differencesPatientsRadiotherapyThymomaSurgeryTumors
2014
Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, Guerrera F, Detterbeck F, Committee E. Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 103-109.e2. PMID: 25308116, DOI: 10.1016/j.jtcvs.2014.08.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemotherapy, AdjuvantDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNeuroendocrine TumorsProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsThymectomyThymus NeoplasmsTime FactorsTreatment OutcomeYoung AdultConceptsInternational Thymic Malignancy Interest GroupMasaoka-Koga stageOverall survivalCompleteness of resectionPrimary neuroendocrine tumorThoracic Surgeons databasePrognostic factorsHistologic subtypeSurgeons databaseNeuroendocrine tumorsHigher biologic aggressivenessMasaoka-Koga stage ICommon histologic subtypeMedian overall survivalEuropean SocietyRetrospective multicenter studyKaplan-Meier methodStrong prognostic factorLog-rank testInduction therapyAdjuvant treatmentCumulative incidenceResection statusComplete resectionMulticenter study